ReviewMedical oncology (Northwood, London, England)2025
Deciphering the molecular landscape of acute myeloid leukemia initiation and relapse: a systems biology approach.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Myeloid Leukemia (AML) patient-derived Mesenchymal Stem Cells (MSCs) behave differently than normal ones, creating a more protective environment for leukemia cells, making relapse harder to prevent. This study aimed to identify prognostic biomarkers and elucidate relevant biological pathways in AML by leveraging microarray data and advanced bioinformatics techniques. We retrieved the GSE122917 dataset from the NCBI Gene Expression Omnibus and performed differential expression analysis (DEA) within R Studio to identify differentially expressed genes (DEGs) among healthy donors, newly diagnosed AML patients, and relapsed AML patients. Data normalization and DEA were achieved using the PLIER method and Plotrix package, with quality assessment performed through visual box plots. Functional enrichment analyses and KEGG pathway analysis illuminated the biological processes associated with DEGs. Network interactions were visualized using Cytoscape software. Survival analysis is performed through Kaplan-Meier plotter. Our analysis revealed a significant downregulation of NCAPG, UBE2C, CDC20, and CDK1, alongside the upregulation of SPP1, as key genes implicated in both the initiation and relapse phases of AML. Survival analysis indicated that lower expression levels of NCAPG, UBE2C, CDC20, and CDK1, and higher levels of SPP1, were correlated with poorer event-free survival (EFS). Additionally, the study highlighted the cell cycle as pivotal in leukemia initiation and progression, while the p53 pathway emerged as critical during the relapse phase. Our findings suggest that NCAPG, UBE2C, CDC20, CDK1, and SPP1 may serve as prognostic biomarkers for AML management, especially through their interaction with the p53 pathway in disease progression. These insights underscore the potential for targeting the p53 pathway and integrating these biomarkers to enhance outcomes for AML patients.
Indexed as
Identifiers
40928707What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.